Skip to content

Bedaquiline

Diarylquinoline Antimycobacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: bedaquiline fumarate, sirturo, TMC207

OnpFDA approvedPMDA approvedOrphan designationATC J04AK05

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Bedaquiline is an onp drug in the Diarylquinoline Antimycobacterial class catalogued in DrugCentral. It was first approved by the FDA in 2012. DrugCentral lists 4 molecular targets, including atpE, KCNH2 and atpE. Recorded indications include Drug resistant tuberculosis and Pulmonary tuberculosis.

  • Approval status: onp (first approved 2012 by the FDA).
  • Drug class: Diarylquinoline Antimycobacterial.
  • Molecular targets: atpE, KCNH2, atpE and atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB (4 listed in DrugCentral).
  • Indications: Drug resistant tuberculosis and Pulmonary tuberculosis.
  • ATC code: J04AK05 (Other drugs for treatment of tuberculosis).
  • Molecular formula: C32H31BrN2O2; molecular weight 555.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Drug resistant tuberculosis
  • Pulmonary tuberculosis

Mechanism & targets

Established pharmacologic classDiarylquinoline Antimycobacterial

Molecular targets (4)

TargetGeneActionActivity
ATP synthase subunit catpEunknownIC50 8.60
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 6.43
ATP synthase subunit catpEunknownKd 6.30
ATP synthaseatpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpBinhibitor—

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2018-01-19PMDA—Janssen Pharmaceutical KK
2012-12-28FDA—JANSSEN THERAPYes

ATC classification

ATC codeTherapeutic hierarchy
J04AK05ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOBACTERIALS › DRUGS FOR TREATMENT OF TUBERCULOSIS › Other drugs for treatment of tuberculosis

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Electrocardiogram QT prolonged1827.0
Neuropathy peripheral772.7
Hepatotoxicity695.1
Anaemia479.2
Off label use243.2
Optic neuritis236.2
Drug resistance165.8
Intentional product use issue161.1
Cardiopulmonary failure126.0
Drug-induced liver injury125.7
Death120.6
Aspartate aminotransferase increased113.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Bedaquiline is on its molecule page.

Molecular formulaC32H31BrN2O2
Molecular weight555.52 g/mol
CAS number843663-66-1
InChIKeyQUIJNHUBAXPXFS-XLJNKUFUSA-N
PubChem CID5388906
COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bedaquiline used for?

DrugCentral lists the following indications for Bedaquiline: Drug resistant tuberculosis and Pulmonary tuberculosis.

How does Bedaquiline work?

Its molecular targets in DrugCentral include atpE, KCNH2, atpE and atpE|atpD|atpA|atpG|atpC|atpFH|atpF|atpB (inhibitor).

When was Bedaquiline first approved?

Bedaquiline was first approved by the FDA in 2012.

What drug class does Bedaquiline belong to?

Bedaquiline is in the Diarylquinoline Antimycobacterial class.

What is the chemical formula of Bedaquiline?

Bedaquiline has the molecular formula C32H31BrN2O2 and a molecular weight of 555.52 g/mol.

Browse: all drugs starting with B · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2012-12-28
AgencyFDA
Targets4
Indications2
FormulaC32H31BrN2O2
DrugCentral ID4741
Interactive profile